Venus Remedies received its first global Marketing Authorization from Saudi FDA for oncology drug Plerixafor 24mg/1.2ml.
The approval advances the company's strategic shift into complex, higher-value specialty injectables for regulated markets.
Plerixafor is a stem cell mobilizer used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma patients.
Saudi Arabia's pharmaceutical market is projected to grow from $12.1B in 2026 to $17.1B by 2033 at 5.0% CAGR.